News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article analyzes Newamsterdam Pharma Company N.v. (NAMS) through quantitative research, highlighting divergent sentiment and a test of support. It provides three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss points. The analysis also includes multi-timeframe signal strengths, …
NewAmsterdam Pharma (NAMS) reported a significant revenue drop and wider net loss in Q2 2026, with sales falling to US$3.7 million from US$19.15 million year-over-year and losses widening to US$64.14 million. This financial downturn, coupled with a 20% share price decrease, complicates the company's …
HC Wainwright has lowered its FY2027 EPS forecast for NewAmsterdam Pharma (NASDAQ:NAMS) to $2.15, down from $2.36, while maintaining a "Moderate Buy" consensus rating for the stock with an average price target of $49.33. The company recently reported a quarterly loss of $0.52 per …
NewAmsterdam Pharma has issued inducement equity awards to three new non-executive hires under its 2024 Inducement Plan. These awards include share options for 28,000 ordinary shares with an exercise price of $27.79 and restricted stock units for 8,200 ordinary shares. The options vest over …
NewAmsterdam Pharma has granted inducement equity awards to three new non-executive hires, consisting of 28,000 share options and 8,200 restricted stock units (RSUs). The share options have an exercise price of $27.79 and vest over four years, while the RSUs vest over three years …
NewAmsterdam Pharma announced that its Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4) for new hires. These grants include share options for 28,000 ordinary shares and restricted stock units for 8,200 ordinary shares, both intended to incentivize new non-executive employees to join …
This article provides an AI-generated analysis of Newamsterdam Pharma Company N.v. Warrant (NASDAQ: NAMSW), focusing on volatility zones as tactical triggers for trading. It outlines institutional trading strategies tailored to different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe …
FMR LLC and Abigail P. Johnson have reported a significant ownership stake in NewAmsterdam Pharma Co N.V. (NAMS), collectively holding 10,339,663 shares of common stock, which represents 8.8% of the class as of June 30, 2026. FMR LLC has sole voting power over 10,329,760 …
NewAmsterdam Pharma Co N.V. (NAMS) reported a significant decline in Q2 2026 revenue to $3.7M from $19.1M year-over-year, alongside a widened net loss of $64.1M, or $0.52 diluted EPS. This downturn is attributed to lower partner-derived receipts after a one-time 2025 development installment and …
NewAmsterdam Pharma provided a corporate update and reported its second quarter financial results. The company highlighted recent achievements and ongoing clinical trials, offering insights into its financial position and future strategic directions. This update serves to inform stakeholders about the company's progress and performance.
NewAmsterdam Pharma outlined its strategy for obicetrapib, emphasizing the ongoing PREVAIL cardiovascular outcomes trial and commercial preparations for a potential European launch. The company expects to reach its interim event target for the PREVAIL trial by year-end, with an independent review in Q1 2027. …
NewAmsterdam Pharma Company N.V. (NAMS) reported a Q2 loss of $0.52 per share, missing the Zacks Consensus Estimate of a $0.48 loss, and revenues of $3.7 million, falling short of estimates by 45.41%. The company has underperformed the S&P 500 this year, with its …
NewAmsterdam Pharma Company N.V. has reported its financial results for the quarter ended June 30. The earnings summary was provided by Refinitiv and featured on TradingView News. The full article content is behind a paywall requiring a subscription to TradingView for unlimited access.
This article analyzes Newamsterdam Pharma Company N.v. (NASDAQ: NAMS), highlighting weak near and mid-term sentiment that could challenge its long-term positive outlook. The analysis provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and …
Janus Henderson Group PLC reduced its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 3.5% in the first quarter, selling 82,739 shares but retaining 2.26 million shares valued at $72.3 million. Despite this sale, institutional investors hold a significant 89.89% of the company, and …
NewAmsterdam Pharma Company NV (NAMS) shows strong fundamentals and high growth potential, despite recent weak stock performance. The company's valuation is considered fair within the Biotechnology & Medical Research industry, and institutional ownership is very high. Analysts widely rate NAMS as a Buy, with …
NewAmsterdam Pharma (Nasdaq: NAMS) announced it will host an Investor Day for analysts and investors on August 5, 2026, in New York City, featuring members of its management team. The event will include a live webcast and will focus on the company's progress in …
NewAmsterdam Pharma (Nasdaq: NAMS) will host an Investor Day on August 5, 2026, in New York City to discuss its late-stage cholesterol-lowering drug, obicetrapib. The event will feature presentations from the company's leadership and will cover ongoing Phase 3 programs like the PREVAIL cardiovascular …
NewAmsterdam Pharma Company N.V. (GETTEX:KH6) generated 19.16 million EUR in revenue last year, primarily from its Transformative Therapies for Cardio-metabolic Diseases segment. This represents a decrease from the 44.01 million EUR reported in the previous year. The company's largest revenue contribution came from Italy.
NewAmsterdam Pharma Company NV (NAMS) currently has a valuation score of 6.93, placing it in the lower quartile of the Biotechnology & Medical Research industry. The company's P/E ratio stands at -16.99, indicating a significant deviation from its recent high and low P/E values. …
This article presents the quarterly and annual income statements for NewAmsterdam Pharma Company NV (NAMS), providing detailed financial figures such as revenue, operating expenses, net income, and earnings per share. It also includes FAQs explaining how to interpret income statements and key metrics for …
NewAmsterdam Pharma Company NV (NAMS) is trading at $29.64, down 2.98%. The company, which specializes in therapies for cardiometabolic diseases, has strong fundamentals and high growth potential, with analysts rating it a "Buy." Despite recent market underperformance, its valuation is considered fair, and institutional …
The EU's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for NewAmsterdam Pharma and Menarini's cholesterol-lowering drugs, Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe). This recommendation supports EU marketing authorization for treating primary hypercholesterolemia, including heterozygous familial hypercholesterolemia. The final decision …
NewAmsterdam Pharma (NAMS) received a positive CHMP opinion from the EMA for its drugs Ubeslo and Evlarco, recommending EU-wide marketing authorization for primary hypercholesterolemia. This development validates the clinical program and brings the company closer to royalty and milestone economics in Europe through its …
NewAmsterdam Pharma (Nasdaq: NAMS) has received a positive opinion from the European Medicines Agency's CHMP for its cholesterol therapies, Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination). This recommendation, based on strong Phase 3 clinical trial data showing significant LDL-C reductions, is …
NewAmsterdam Pharma and Menarini Group received a positive opinion from the European Medicines Agency's CHMP recommending EU marketing authorization for two cholesterol-lowering treatments, Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination). This recommendation is based on positive Phase 3 clinical trial data …
Search by ticker symbol or company name and select a result to open its chart.